StockData
OraSure Technologies Inc logo

OraSure Technologies Inc (OSUR) company profile

OSURNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q/A on Nov 12, 2026Score 11/3037% below fair value
$3.51−0.09 (-2.50%)

Close on Nov 17, 2026Market cap $242.08MP/E –Yield –

About OraSure Technologies

Surgical & Medical Instruments & Apparatus, SIC 3841

OTI, also known as OraSure Technologies, develops, manufactures, and distributes rapid diagnostic testing products and sample management solutions. Its diagnostic line features rapid point-of-care and over-the-counter self-tests for infectious conditions including HIV, Hepatitis C, COVID-19, and sickle cell disease under brand names like OraQuick and InteliSwab. The company also provides sample collection devices and stabilization solutions for genetic and microbiome research. It serves healthcare providers, clinical and academic laboratories, public health agencies, pharmaceutical firms, and retail consumers directly and through commercial partners.

The company operates manufacturing and distribution facilities in Bethlehem, Pennsylvania, while sourcing additional assembly and production services through long-term partner relationships in Canada and Thailand. As of late 2025, the organization employs 500 full-time personnel across its business operations. Products are marketed domestically within the United States as well as internationally across Europe, Canada, and various global markets through internal sales forces and independent distributors.

Summary of the business section of OraSure Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
OraSure Technologies Inc
Headquarters
Bethlehem, PA
Address
220 E First St 18015
Phone
(503) 641-6115
Employees
500, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Philadelphia, PA

Stock & identifiers

Ticker
OSUR
Exchange
Nasdaq
IPO date
Nov 17, 1986
Shares outstanding
69M, Jul 31, 2026
Public float
$218.47M, Jun 30, 2025
Filer category
Accelerated filer
Stock splits
3-for-1, Apr 8, 1987
SEC CIK
1116463
CUSIP
68554V108
ISIN
US68554V1089
FIGI
BBG000J3D1Y8
Share class FIGI
BBG001SD3BW5
LEI
529900GNNJPNM4XHXQ77
EIN
36-4370966

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Manner Carrie EglintonPresident & CEO, Director2,190,874
Kenneth J. McGrathChief Financial Officer589,562
Michele Marie AnthonySVP Finance & CAO185,788
Kathleen Gallagher WeberChief Product Officer399,518
Steven Kyle BoydDirector168,031
John P. KennyDirector204,598
Robert W. McMahonDirector123,137
Lelio MarmoraDirector148,460
Nancy J. GaglianoDirector185,055
John D. BertrandDirector79,767
Mara G. AspinallDirector178,758
David ShulkinDirector126,335

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.29M$671.23K$1.58M$23$81
FY2024$5.60M-$5.71M$1.54M$45$85
FY2023$6.70M$13.79M$1.60M$102$106
FY2022
Carrie Eglinton Manner
$6.75M$6.65M$1.46M$60$99
FY2022
Nancy Gagliano M.d.
$940.29K$347.56K$1.46M$60$99
FY2022
Stephen S.Tang Ph.d.
$2.77M$714.65K$1.46M$60$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Carrie Eglinton Manner
President and Chief Executive Officer
$721.00K$3.39M$173.04K$4.00K$4.29M-23%
Kenneth McGrath
Chief Financial Officer
$512.00K$738.77K$61.44K$4.00K$1.32M-22%
Kathleen G. Weber
Former Chief Product Officer
$421.15K$647.02K–$768.27K$1.84M+31%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, the Company had 500 full-time employees, which compares to 501 employees as of December 31, 2024.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?